How to buy AzurRx BioPharma stock

AzurRx BioPharma, Inc is a biotechnology business based in the US. AzurRx BioPharma shares (AZRX) are listed on the NASDAQ and all prices are listed in US Dollars. AzurRx BioPharma employs 12 staff and has a market cap (total outstanding shares value) of 0.00.

AzurRx BioPharma share price

Use our graph to track the performance of AZRX stocks over time.

AzurRx BioPharma shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$0.61 - $2.50
50-day moving average	$1.11
200-day moving average	$1.06
Wall St. target price	$3.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.90

Buy AzurRx BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AzurRx BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of AzurRx BioPharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AzurRx BioPharma financials

Gross profit TTM	$0
Return on assets TTM	-151.38%
Return on equity TTM	-3305.91%
Profit margin	0%
Book value	$0.49
Market capitalisation	$68.1 million

TTM: trailing 12 months

Shorting AzurRx BioPharma shares

There are currently 1.8 million AzurRx BioPharma shares held short by investors – that's known as AzurRx BioPharma's "short interest". This figure is 16% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting AzurRx BioPharma shares can be evaluated.

AzurRx BioPharma's "short interest ratio" (SIR)

AzurRx BioPharma's "short interest ratio" (SIR) is the quantity of AzurRx BioPharma shares currently shorted divided by the average quantity of AzurRx BioPharma shares traded daily (recently around 5.9 million). AzurRx BioPharma's SIR currently stands at 0.31. In other words for every 100,000 AzurRx BioPharma shares traded daily on the market, roughly 310 shares are currently held short.

However AzurRx BioPharma's short interest can also be evaluated against the total number of AzurRx BioPharma shares, or, against the total number of tradable AzurRx BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AzurRx BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AzurRx BioPharma shares in existence, roughly 20 shares are currently held short) or 0.0249% of the tradable shares (for every 100,000 tradable AzurRx BioPharma shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AzurRx BioPharma.

Find out more about how you can short AzurRx BioPharma stock.

AzurRx BioPharma share dividends

We're not expecting AzurRx BioPharma to pay a dividend over the next 12 months.

AzurRx BioPharma share price volatility

Over the last 12 months, AzurRx BioPharma's shares have ranged in value from as little as $0.61 up to $2.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AzurRx BioPharma's is 1.6551. This would suggest that AzurRx BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AzurRx BioPharma overview

AzurRx BioPharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc.

Frequently asked questions

• What percentage of AzurRx BioPharma is owned by insiders or institutions?

  Currently 1.026% of AzurRx BioPharma shares are held by insiders and 2.613% by institutions.

• How many people work for AzurRx BioPharma?

  Latest data suggests 12 work at AzurRx BioPharma.

• When does the fiscal year end for AzurRx BioPharma?

  AzurRx BioPharma's fiscal year ends in December.

• Where is AzurRx BioPharma based?

  AzurRx BioPharma's address is: 1615 South Congress Avenue, Delray Beach, FL, United States, 33445

• What is AzurRx BioPharma's ISIN number?

  AzurRx BioPharma's international securities identification number is: US05502L1052

• What is AzurRx BioPharma's CUSIP number?

  AzurRx BioPharma's Committee on Uniform Securities Identification Procedures number is: 05502L105